Literature DB >> 12199486

Guidelines for the management of chronic obstructive pulmonary disease.

A S Buist1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a respiratory condition characterized by progressive decline in lung function. It imposes a considerable burden on patients, healthcare services and society that is likely to increase in the future. It is, therefore, important to ensure that this disease is managed as effectively as possible. In many therapeutic areas, management guidelines have been developed in an attempt to ensure that physicians are aware of optimal disease management and cost-effective use of healthcare resources. Such guidelines are usually prepared by consensus among clinical experts or following a systematic review of the evidence. However, there are a number of barriers to the implementation of treatment guidelines, including the sheer weight of guidelines in all therapeutic areas, a focus on scientific knowledge rather than on clinical practice, lack of trust in the recommendations, practical considerations (e.g. time, resources, budget) and failure to include the perspective of patients. The management guidelines most likely to be implemented are those that are quick and easy to use, relevant to the user's practice and from a credible source. In COPD, over 40 guidelines have been developed, mainly by local respiratory societies as a result of local expert consensus. The guidelines developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) are evidence-based and have the backing of international experts. Local implementation plans have been developed to help ensure that GOLD recommendations are implemented in practice. In all COPD guidelines, however, lung function measures feature prominently with limited reference to outcome measures of interest to patients and healthcare payers (e.g. frequency of exacerbations requiring hospitalization). Low expectations among physicians and patients may also impair implementation. In conclusion, guidelines may improve the management of COPD, but the main challenge is to ensure implementation.

Entities:  

Mesh:

Year:  2002        PMID: 12199486     DOI: 10.1016/s0954-6111(02)80029-4

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  8 in total

1.  Biomedical risk assessment as an aid for smoking cessation.

Authors:  Carole Clair; Yolanda Mueller; Jonathan Livingstone-Banks; Bernard Burnand; Jean-Yves Camain; Jacques Cornuz; Myriam Rège-Walther; Kevin Selby; Raphaël Bize
Journal:  Cochrane Database Syst Rev       Date:  2019-03-26

Review 2.  Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review.

Authors:  Raphaël Bize; Bernard Burnand; Yolanda Mueller; Jacques Cornuz
Journal:  Tob Control       Date:  2007-06       Impact factor: 7.552

3.  Respiratory resistance of patients during cardiac stress testing with adenosine: is dyspnea a sign of bronchospasm?

Authors:  Eva Fricke; Elke Esdorn; Annett Kammeier; Harald Fricke; Rainer Preuss; Wolfgang Burchert; Oliver Lindner
Journal:  J Nucl Cardiol       Date:  2008 Jan-Feb       Impact factor: 5.952

4.  Effect of an integrated primary care model on the management of middle-aged and old patients with obstructive lung diseases.

Authors:  Marianne A Meulepas; Johanna E Jacobs; Frank W J M Smeenk; Ivo Smeele; Annelies E M Lucas; Ben J A M Bottema; Richard P T M Grol
Journal:  Scand J Prim Health Care       Date:  2007-09       Impact factor: 2.581

5.  Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.

Authors:  Carl Victor Asche; Shelah Leader; Craig Plauschinat; Swetha Raparla; Ming Yan; Xiangyang Ye; Dave Young
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-03-15

6.  Screening of long non-coding RNA and TUG1 inhibits proliferation with TGF-β induction in patients with COPD.

Authors:  Wenxiang Tang; Zhenyu Shen; Jiang Guo; Shenghua Sun
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-11-28

7.  Epidemiological evidence relating risk factors to chronic obstructive pulmonary disease in China: A systematic review and meta-analysis.

Authors:  Hong Chen; Xiang Liu; Xiang Gao; Yipeng Lv; Liang Zhou; Jianwei Shi; Wei Wei; Jiaoling Huang; Lijia Deng; Zhaoxin Wang; Ying Jin; Wenya Yu
Journal:  PLoS One       Date:  2021-12-28       Impact factor: 3.240

Review 8.  Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Authors:  Marc Miravitlles; Nicolas Roche; João Cardoso; David Halpin; Zaurbek Aisanov; Hannu Kankaanranta; Vladimir Kobližek; Paweł Śliwiński; Leif Bjermer; Michael Tamm; Francesco Blasi; Claus F Vogelmeier
Journal:  Respir Res       Date:  2018-01-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.